drugset / Trial / NCT04184505
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
RandomizedParallel-groupOpen-labelTreatment
Summary
Open-label, randomized multicenter phase III non-inferiority study
Timeline
- Start
- 2020-11-27
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Daunorubicin | Small molecule | 60 mg/m2 | Intravenous |